This is 100% normal and part of the growth of a strong company with excellent fundamentals and an FDA approval coming this year.

$ARDX very good fda news on this conference call

And this is just a beginning, FDA approval will take it to the skies.

Pretty Bullish ER going to give us an update on FDA when and etc. .

If the trend of script numbers is anything to go by, guidance could be way better than Wall Street expects giving us a nice boost before FDA news.

$AKBA within 3 to 4 weeks this stock could be over 2 heading to three like $ARDX .. gsk approval has helped.. fda news, ema opinion/ approval, partnership..

$ARDX when we get fda approval will be shining

This should be seen as a REALLY good thing - because they will need cashflow soon - one would expect - assumption being FDA response is close and production and marketing is about to get kicked up a notch. .

Things to look forward to.. NDA refile announcement, Q4 results, weekly IBSRELA sales increasing now that we are through the holidays, FDA approval, Japan approval, launch of Xphozah.

They just got approval for 1 drug from FDA and things are bot going well there..

Easy $200 buy June with Duchenne Muscular Dystrophy FDA approval coming.

Easy $200 buy June with Duchenne Muscular Dystrophy FDA approval coming.

Good FDA news -- stock is up!

we can hear about FDAs decision anyday starting Thursday..exciting times ahead

but a positive for the FDA as Dr. Stein looks at the label.

*******” another BIG reason why the FDA should approve it!!! !

Home run with FDA, path forward soon.

And some are saying oh its just an opinion, this is actually fantastic news for us and will open the door to other countries for approval and HOPEFULLY the US fda will approve it.

$AKBA We should be very happy at current recovery, Im holding the rest of my position right into partner, FDA the lot Yesterdays news was amazing

It is clean for the FDA.

This bodes very well for fda FDRR approval.

$AKBA FDA, please listen and read: “The benefit of Vafseo is its ability to correct haemoglobin levels in dialysis-dependent patients, with effects comparable to those seen with erythropoiesis-stimulating agents.